Get the Stockscreener App
0.2916
2.43%
-0.00725
After Hours:
.31
0.0184
+6.31%
Iterum Therapeutics Plc stock is traded at $0.2916, with a volume of 378.48K.
It is down -2.43% in the last 24 hours and down -11.10% over the past month.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
See More
Previous Close:
$0.2989
Open:
$0.2988
24h Volume:
378.48K
Relative Volume:
0.46
Market Cap:
$15.54M
Revenue:
-
Net Income/Loss:
$-24.08M
P/E Ratio:
-0.3402
EPS:
-0.8572
Net Cash Flow:
$-14.75M
1W Performance:
+2.24%
1M Performance:
-11.10%
6M Performance:
-62.28%
1Y Performance:
-79.32%
1-Day Range:
$0.2815
$0.3064
1-Week Range:
$0.2815
$0.3165
52-Week Range:
$0.26
$1.58
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Name
Iterum Therapeutics Plc
Sector
Industry
Phone
(872) 225-6077
Address
3 DUBLIN LANDINGS, DUBLIN 1
Compare ITRM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.2916 | 15.93M | 0 | -24.08M | -14.75M | -0.8572 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-21 | Upgrade | Gabelli & Co | Sell → Hold |
| Mar-15-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-21-20 | Downgrade | Gabelli & Co | Buy → Sell |
| Dec-11-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Iterum Therapeutics Plc Stock (ITRM) Latest News
Published on: 2026-02-12 20:05:19 - baoquankhu1.vn
Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Friday - Defense World
Investment Review: What dividend growth rate does CTNT offerEarnings Trend Report & Low Risk High Reward Ideas - baoquankhu1.vn
Gap Down: Is UPSD stock a good pick for beginners2025 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
Fed Meeting: How correlated is W R Berkley Corporation to the S P500July 2025 Gainers & Verified Swing Trading Watchlist - baoquankhu1.vn
ITRM Stock Price, Forecast & Analysis | ITERUM THERAPEUTICS PLC (NASDAQ:ITRM) - Chartmill
Portfolio Recap: Is Iterum Therapeutics plc stock risky to hold now2025 Earnings Impact & Community Trade Idea Sharing Platform - baoquankhu1.vn
Weekly Earnings: How does Hovnanian Enterprises Inc compare to its peersRate Cut & Real-Time Price Movement Reports - baoquankhu1.vn
Activity Recap: What are the future prospects of Iterum Therapeutics plcMarket Sentiment Report & Fast Gaining Stock Reports - baoquankhu1.vn
Patterns Watch: Is Iterum Therapeutics plc stock a safe haven assetLayoff News & Low Risk Entry Point Tips - Bộ Nội Vụ
Will Iterum Therapeutics plc stock benefit from green energy trendsJuly 2025 Earnings & Daily Profit Focused Screening - Улправда
Is Iterum Therapeutics plc stock overvalued by current metricsProfit Target & High Return Trade Opportunity Guides - ulpravda.ru
Will Iterum Therapeutics plc stock benefit from sector rotationInflation Watch & Safe Capital Growth Stock Tips - Улправда
Can Iterum Therapeutics plc stock deliver surprise earnings beatWeekly Trade Report & Expert Curated Trade Setup Alerts - Улправда
Why Iterum Therapeutics plc stock remains a top recommendationStock Buyback Updates & Market Monitoring and Alerts - Улправда
Iterum Therapeutics expands market access for ORLYNVAH antibiotic - Investing.com
Iterum Therapeutics provides business update - marketscreener.com
Iterum Therapeutics Provides Business Update - The Manila Times
New antibiotic ORLYNVAH could reach 34M+ people pending FDA feedback - Stock Titan
Analyzing Iterum Therapeutics (NASDAQ:ITRM) & Savara (NASDAQ:SVRA) - Defense World
Why hedge funds are buying Iterum Therapeutics plc stockWeekly Trade Analysis & Capital Efficient Trade Techniques - Улправда
Iterum Therapeutics secures major PBM agreement for antibiotic By Investing.com - Investing.com Nigeria
Iterum Therapeutics (ITRM) Secures Key PBM Agreement and Expands Patent Portfolio - GuruFocus
Iterum Therapeutics secures major PBM agreement for antibiotic - Investing.com
New PBM deal could open ORLYNVAH access to 40M more people in 2026 - Stock Titan
Iterum Therapeutics faces Nasdaq listing compliance challenge - MSN
Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge - The Globe and Mail
Iterum Therapeutics receives Nasdaq notice on listing compliance By Investing.com - Investing.com Australia
Iterum Therapeutics plc Stock Analysis and ForecastEarnings Forecast Updates & Fast Profit Stock Ideas - earlytimes.in
Iterum Therapeutics receives Nasdaq notice on listing compliance - Investing.com
Iterum Therapeutics (NASDAQ: ITRM) discloses Nasdaq delisting risk on value, price - Stock Titan
Iterum Therapeutics Plc (ITRM) can make a big difference with a little luck - setenews.com
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH By Investing.com - Investing.com Nigeria
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH - Investing.com
ITRM Expands ORLYNVAH Access and Secures Key Medicare Part D Agr - GuruFocus
Iterum Therapeutics (Nasdaq: ITRM) inks Medicare Part D deal, EU patent to 2039 - Stock Titan
Iterum Therapeutics (ITRM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Taking on analysts’ expectations and winning: Iterum Therapeutics Plc (ITRM) - setenews.com
Iterum Therapeutics Plc (ITRM) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Iterum’s antibiotic ORLYNVAH now available through McKesson By Investing.com - Investing.com Nigeria
Iterum’s antibiotic ORLYNVAH now available through McKesson - Investing.com
Iterum Therapeutics (ITRM) Expands Product Availability and FDA Clearance - GuruFocus
Iterum (NASDAQ: ITRM) Adds McKesson for ORLYNVAH as Sulopenem Disc Gains FDA 510(k) - Stock Titan
Q3 2025 Iterum Therapeutics PLC Earnings Call Transcript - GuruFocus
Is Iterum Therapeutics plc stock attractive after correctionPortfolio Update Report & Growth Oriented Trading Recommendations - newser.com
Why retail investors favor Iterum Therapeutics plc stockJuly 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Iterum Therapeutics Plc Stock (ITRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):